Carin E Binder

Suggest Changes
Learn More
BACKGROUND The thrice daily dosing regimen of immediate release methylphenidate (IR-MPH) for Attention Deficit/Hyperactivity Disorder (ADHD) requires in-school dosing, leading to issues surrounding(More)
OBJECTIVE This pilot, uncontrolled, open-label study evaluated the safety/tolerability and potential effectiveness of OROS-methylphenidate (OROS-MPH) in adult attention deficit hyperactivity disorder(More)
OBJECTIVE To evaluate the efficacy, safety, and tolerability of adjunctive osmotic-release oral system (OROS) methylphenidate in outpatients with major depressive disorder (MDD) receiving a stable(More)
OBJECTIVE To determine the safety and effectiveness of long-acting injectable risperidone (LAI-ris) add-on in bipolar patients. METHOD A 6-month, open-label, randomized, pilot trial enrolled 49(More)